Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome

Noelle Voort van Zyp, JGHG Prevost, Mischa Hoogeman, John Praag, Ronnie van der Holt, Peter Levendag, RJ Klaveren, Peter Pattynama, J.J.M.E. Nuyttens

Research output: Contribution to journalArticleAcademicpeer-review

187 Citations (Scopus)


Purpose: To report the clinical outcome of treatment using real-time tumor tracking for 70 patients with inoperable stage I non-small cell lung cancer (NSCLC). Materials and methods: Seventy inoperable patients with peripherally located early-stage NSCLC were treated with 45 or 60 Gy in three fractions using CyberKnife. Pathology was available in 51% of patients. Thirty-nine patients had a T1-tumor and 31 had a T2-tumor. Markers were placed using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk of pneumothorax. Results: The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared to 78% for patients treated with a total dose of 45 Gy (p = 0.197). All local recurrences (n = 4) occurred in patients with T2-tumors. Overall survival for the whole group at two years was 62% and the cause specific survival was 85%. The median follow-up was 15 months. Grade 3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade 3 toxicity occurred in 7 patients (10%). No grade >= 4 toxicity occurred. Conclusion: Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in three fractions for NSCLC patients treated with the real-time tumor tracking. Toxicity was low. (C) 2009 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 91 (2009) 296-300
Original languageUndefined/Unknown
Pages (from-to)296-300
Number of pages5
JournalRadiotherapy and Oncology
Issue number3
Publication statusPublished - 2009

Research programs

  • EMC MM-03-32-04
  • EMC MM-04-42-02
  • EMC NIHES-03-30-01

Cite this